KRRO Korro Bio, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$11.96

Period return

+1.45 (+13.80%)

Volume

233.6K

2026-07-21O $11.74 H $12.09 L $11.62 C $11.96MA5 $12.2MA20 $13.31MA60 $12.33MA120 $12.27

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 19.LowBUY2 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 05. 18.MediumBUY2 months ago
Citigroup: Buy
US analyst rating / recommendation change.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.00%
2026. 05. 07.High3 months ago
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 03. 13.LowBUY4 months ago
Cantor Fitzgerald: Overweight
US analyst rating / recommendation change.
2026. 03. 13.MediumBUY4 months ago
Raymond James: Outperform
US analyst rating / recommendation change.
2026. 02. 19.MediumBUY5 months ago
Clear Street: Buy
US analyst rating / recommendation change.
2026. 02. 18.MediumBUY5 months ago
William Blair: Outperform
US analyst rating / recommendation change.
2026. 01. 29.MediumBUY6 months ago
Chardan Capital: Buy
US analyst rating / recommendation change.
2026. 01. 29.MediumBUY6 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $19.89 · 9 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
HQ: Cambridge, MA, United States
Fiscal year end: —
Employees: 49
IPO date: —

View details →

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 05. 07.	After market close (AMC)	$-1.18	—	—	$166.67K	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$-2.49	—	—	$2.55M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-7.11	—	—	$0	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-4.87	—	—	$0	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	165,472	$1.87M	0.00%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	78,984	$632.66K	0.00%	—	New position

Korro Bio, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 19.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 05. 18.	Citigroup	—	Initiate coverage	— → Buy	—	Citigroup: Buy
2026. 03. 13.	Cantor Fitzgerald	—	Maintain	Overweight → Overweight	—	Cantor Fitzgerald: Overweight
2026. 03. 13.	Raymond James	—	Upgrade	Market Perform → Outperform	—	Raymond James: Market Perform → Outperform
2026. 02. 19.	Clear Street	—	Upgrade	Hold → Buy	—	Clear Street: Hold → Buy
2026. 02. 18.	William Blair	—	Upgrade	Market Perform → Outperform	—	William Blair: Market Perform → Outperform